IL1-blocking therapy in colchicine-resistant familial Mediterranean fever
Approximately 10%-20% of patients with familial Mediterranean fever (FMF) show an inadequate response to colchicine. In our cohort study, patients with FMF with or without amyloidosis and with an inadequate response to colchicine were treated with anakinra or canakinumab.
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
12 October 2018
|
| In: |
European Journal of Rheumatology
Year: 2018, Jahrgang: 5, Heft: 4, Pages: 230-234 |
| ISSN: | 2148-4279 |
| DOI: | 10.5152/eurjrheum.2018.18036 |
| Online-Zugang: | Verlag: http://www.eurjrheumatol.org/en/il1-blocking-therapy-in-colchicine-resistant-familial-mediterranean-fever-133159 Resolving-System, Volltext: https://doi.org/10.5152/eurjrheum.2018.18036 
|
| Verfasserangaben: | Birgit Maria Köhler, Hanns-Martin Lorenz, Norbert Blank |
| Zusammenfassung: | Approximately 10%-20% of patients with familial Mediterranean fever (FMF) show an inadequate response to colchicine. In our cohort study, patients with FMF with or without amyloidosis and with an inadequate response to colchicine were treated with anakinra or canakinumab. |
|---|---|
| Beschreibung: | Die angegeben DOI ist nicht mit dem Artikel verlinkt Gesehen am 06.12.2019 |
| Beschreibung: | Online Resource |
| ISSN: | 2148-4279 |
| DOI: | 10.5152/eurjrheum.2018.18036 |